The Pathology Core is designed to provide three services to support the experimental aims of this Program Project application. First, the Core will ensure timely and reliable availability of tumor tissues collected from the preclinical studies with genetic models of prostate cancer used in each Project. This will involve schedule-dependent animal harvesting, necropsy, tissue dissection, and tissue processing, including bone lesions. The second objective of Core C is to provide histopathological evaluation of signaling pathways in localized and metastatic prostate cancer, as well as bone-tumor interplay after treatment with the various "network inhibitors" tested in Projects 1, 2, and 3. To accomplish these tasks. Core C will support quantitative and standardized immunohistochemical evaluation of tumor markers, determine parameters of apoptosis and cell proliferation, provide volumetric quantification of lung metastasis by stereologic microscopy, and examine a potential modulation of ancillary pathways of tumor growth, i.e. angiogenesis. Third, Core C will identify, characterize and test molecular biomarkers of pathway and target validation for the proposed preclinical studies, in vivo. This will involve analysis of markers of mitochondrial dysfunction and oxidative damage for Project 1, dynamic changes in integrin signaling for Project 2, and evaluation of a Runx2 "gene signature" for modulation of bone-tumor responses in Project 3. The tasks provided by Core C will support equally each Project, and will be accomplished under the supervision of two senior pathologists. Drs. Irwin Leav, Director of Core C, and Zhong Jiang, Co-Director of Core C, have extensive experience in histopathology of prostate cancer, disease models in rodents, and evaluation of molecular biomarkers of tumor responses. The centralization of the morphologic studies in Core C will facilitate collaborative research among the investigators on this application, while obviating the need for each Project to individually develop key techniques.

Public Health Relevance

The services provided by Core C are pivotal to accomplish the specific aims contained in each Project, and to obtain a comprehensive evaluation of tumor responses after treatment with new molecular therapeutics, i.e. nebwork inhibitors. The combination of high-resolution molecular imaging (Core B) with quantitative and standardized histopathology (Core C) will enhance the synergistic integration of each Project, and strengthen the feasibility of their mechanistic and preclinical goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA140043-05
Application #
8526419
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
5
Fiscal Year
2013
Total Cost
$65,477
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Caino, M Cecilia; Altieri, Dario C (2016) Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy. Clin Cancer Res 22:540-5
Lisanti, Sofia; Garlick, David S; Bryant, Kelly G et al. (2016) Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development. J Biol Chem 291:25247-25254
Lu, Huimin; Wang, Tao; Li, Jing et al. (2016) αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. Cancer Res 76:5163-74
Languino, Lucia R; Singh, Amrita; Prisco, Marco et al. (2016) Exosome-mediated transfer from the tumor microenvironment increases TGFβ signaling in squamous cell carcinoma. Am J Transl Res 8:2432-7
Chae, Young Chan; Vaira, Valentina; Caino, M Cecilia et al. (2016) Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. Cancer Cell 30:257-72
Singh, Amrita; Fedele, Carmine; Lu, Huimin et al. (2016) Exosome-mediated Transfer of αvβ3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype. Mol Cancer Res 14:1136-1146
Farina, Nicholas H; Zingiryan, Areg; Akech, Jacqueline A et al. (2016) A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice. Oncotarget :
Chae, Young Chan; Angelin, Alessia; Lisanti, Sofia et al. (2015) Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun 6:7605
Zhang, Xuhui; Akech, Jacqueline; Browne, Gillian et al. (2015) Runx2-Smad signaling impacts the progression of tumor-induced bone disease. Int J Cancer 136:1321-32
Forno, Irene; Ferrero, Stefano; Russo, Maria Veronica et al. (2015) Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression. PLoS One 10:e0130060

Showing the most recent 10 out of 56 publications